Effects of Intraocular Ranibizumab and Bevacizumab in Transgenic Mice Expressing Human Vascular Endothelial Growth Factor

Ophthalmology

Volumn 116, Issue 9, 2009, Pages 1748-1754

  Miki, Katsuaki ^a   Miki, Akiko ^a   Matsuoka, Masato ^a   Muramatsu, Daisuke ^a   Hackett, Sean F ^a   Campochiaro, Peter A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; DOXYCYCLINE; OPSIN; RANIBIZUMAB; RHODOPSIN; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; FLUORESCENCE MICROSCOPY; GENE OVEREXPRESSION; HISTOPATHOLOGY; MOUSE; NONHUMAN; PHOTORECEPTOR; PRIORITY JOURNAL; PROMOTER REGION; REPRESSOR GENE; RETINA DETACHMENT; SUBRETINAL NEOVASCULARIZATION; TRANSGENIC MOUSE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; DOXYCYCLINE; GENE EXPRESSION REGULATION; INJECTIONS; MICE; MICE, TRANSGENIC; MICROSCOPY, FLUORESCENCE; RETINAL DETACHMENT; RETINAL NEOVASCULARIZATION; RHODOPSIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 69249213967     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2009.05.020     Document Type: Article

References (29)

1. Klein R., Klein B.E., Linton K.P., and DeMets D.L. The Beaver Dam Eye Study: the relation of age-related maculopathy to smoking. Am J Epidemiol 137 (1993) 190-200
2. Tobe T., Ortega S., Luna J.D., et al. Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model. Am J Pathol 153 (1998) 1641-1646
3. Yi X., Ogata N., Komada M., et al. Vascular endothelial growth factor expression in choroidal neovascularization in rats. Graefes Arch Clin Exp Ophthalmol 235 (1997) 313-319
4. Kwak N., Okamoto N., Wood J.M., and Campochiaro P.A. VEGF is an important stimulator in a model of choroidal neovascularization. Invest Ophthalmol Vis Sci 41 (2000) 3158-3164
5. Okamoto N., Tobe T., Hackett S.F., et al. Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization. Am J Pathol 151 (1997) 281-291
6. Tobe T., Okamoto N., Vinores M.A., et al. Evolution of neovascularization in mice with overexpression of vascular endothelial growth factor in photoreceptors. Invest Ophthalmol Vis Sci 39 (1998) 180-188
7. Presta L.G., Chen H., O'Connor S.J., et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57 (1997) 4593-4599
8. Ferrara N., Damico L., Shams N., et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 26 (2006) 859-870
9. Gaudreault J., Fei D., Rusit J., et al. Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 46 (2005) 726-733
10. Mordenti J., Thomsen K., Licko V., et al. Intraocular pharmacokinetics and safety of a humanized monoclonal antibody in rabbits after intravitreal administration of a solution or a PLGA microsphere formulation. Toxicol Sci 52 (1999) 101-106
11. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
12. Rosenfeld P.J., Brown D.M., Heier J.S., et al., MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355 (2006) 1419-1431
13. Brown D.M., Kaiser P.K., Michels M., et al., ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355 (2006) 1432-1444
14. Michels S., Rosenfeld P.J., Puliafito C.A., et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 112 (2005) 1035-1047
15. Nguyen Q.D., Shah S.M., Tatlipinar S., et al. Bevacizumab suppresses choroidal neovascularization due to pathologic myopia [letter]. Br J Ophthalmol 89 (2005) 1368-1370
16. Moshfeghi A.A., Rosenfeld P.J., Puliafito C.A., et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology 113 (2006) 2002-2011
17. Nguyen Q.D., Shah S.M., Hafiz G., et al. Intravenous bevacizumab causes regression of choroidal neovascularization secondary to diseases other than age-related macular degeneration. Am J Ophthalmol 145 (2007) 257-266
18. Rosenfeld P.J., Moshfeghi A.A., and Puliafito C.A. Optical coherence tomography findings after an intavitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 36 (2005) 331-335
19. Avery R.L., Pieramici D.J., Rabena M.D., et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113 (2006) 363-372
20. Spaide R.F., Laud K., Fine H.F., et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26 (2006) 383-390
21. Yu L., Wu X., Cheng Z., et al. Interaction between bevacizumab and murine VEGF-A: a reassessment. Invest Ophthalmol Vis Sci 49 (2008) 522-527
22. Yannuzzi L.A., Negrao S., Iida T., et al. Retinal angiomatous proliferation in age-related macular degeneration. Retina 21 (2001) 416-434
23. Ohno-Matsui K., Hirose A., Yamamoto S., et al. Inducible expression of vascular endothelial growth factor in photoreceptors of adult mice causes severe proliferative retinopathy and retinal detachment. Am J Pathol 160 (2002) 711-719
24. Takahashi K., Saishin Y., Saishin Y., et al. Intraocular expression of endostatin reduces VEGF-induced retinal vascular permeability, neovascularization, and retinal detachment. FASEB J 17 (2003) 896-898
25. Nambu H., Nambu R., Oshima Y., et al. Angiopoietin 1 inhibits ocular neovascularization and breakdown of the blood-retinal barrier. Gene Ther 11 (2004) 865-873
26. Mori K., Duh E., Gehlbach P., et al. Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization. J Cell Physiol 188 (2001) 253-263
27. Kim H., Fariss R.N., Zhang C., et al. Mapping of the neonatal Fc receptor in the rodent eye. Invest Ophthalmol Vis Sci 49 (2008) 2025-2029
28. Elice F., Rodeghiero F., Falanga A., and Rickels F. Thrombosis associated with angiogenesis inhibitors. Best Pract Res Clin Haematol 22 (2009) 115-128
29. Dafer R.M., Schneck M., Friberg T.R., and Jay W.M. Intravitreal ranibizumab and bevacizumab: a review of risk. Semin Ophthalmol 22 (2007) 201-204